—— 要投稿,上万维,轻松学术交流

严正声明

本站非期刊官网,非中介代理,
不向作者收取任何费用!
举报微信:13140028228 冯老师

态度公正、信息求实、投稿自助、使用免费
药物分析学报(英文版)(Journal of Pharmaceutical Analysis)(原:西安医科大学学报》(英文版))
CN外文 - 月刊
  • 药物分析学报(英文版)(Journal of Pharmaceutical Analysis)(原:西安医科大学学报》(英文版))
  • 复合影响因子:1.66
  • CSCD(2025-2026)科技核心(2025学术卷)
  • 知网外文库,万方,维普
  • /有基金 100.0%
  投稿方式:官网投稿
  • 栏目频次
  • 一作占比
  • 单位占比
  • 热词

高频栏目

100%期平均发文量3篇
100%期平均发文量11篇
83.3%期平均发文量1篇

低频栏目

16.7%期平均发文量1篇
16.7%期平均发文量1篇
16.7%期平均发文量1篇
16.7%期平均发文量1篇
100.0%
暂无单位信息.
暂无关键词信息.
  • 更多

    期刊简介

  • 《药物分析学报(英文版)》(Journal of Pharmaceutical Analysis)(月刊),创刊于2011年,由教育部主管,西安交通大学主办,是国内第一本有关药物分析的专业英文学术期刊,主要报道药物分析新方法、新技术,药物发现、药品质量控制、用药安全等最新研究成果。旨在搭建高水平的国际学术交流平台,促进学科发展。

  • 基本信息

  • 期刊名称:药物分析学报(英文版)(Journal of Pharmaceutical Analysis)(原:西安医科大学学报》(英文版))
  • 主管单位:中华人民共和国教育部
  • 主办单位:西安交通大学
  • 国内刊号:CN 61-1484/R
  • 国际刊号:ISSN 2095-1779;EISSN2214-0883
  • 出刊日期:
    期刊定价:
  • 邮发代码:
  • 所在省区:陕西
    邮政编码:
  • 联系地址:

  • 投稿信息

  • 学科分类:医卫综论
    版面费用:待核实
  • 字数要求:4000-46000
    查重要求:-
  • 复合因子:1.66
    综合因子:1.177
  • 审  稿 费:待核实
    稿费:待核实
  • 本刊可发:
  • 特殊属性:第一批认定学术期刊,外文期刊

  • 联系方式

  • 投稿网址:https://www.editorialmanager.com/jpa/
  • 官网网址:https://www.sciencedirect.com/journal/journal-of-pharmaceutical-analysis
  • 电话传真:029-88960092(202506期);82657423(官网信息)
  • 电子邮箱:jpasubmit@126.com;jpa2011@xjtu.edu.cn(202506期)
    jpaeditor@xjtu.edu.cn(官网邮箱)
  • 微信公众号:JPharmAnal

审稿时间:暂无参考数据,审稿时间不确定!

投稿难度:网友分享,仅供参考

见刊周期:-

温馨提示以上只是参考信息,实际情况会根据投稿主题、稿件质量和数量、审稿流程有所差异。想获得更准确信息请联系期刊的编辑部进行咨询。

欢迎点评!让信息更透明,使投稿更轻松!
    • 审稿时间:
      是否录用:
    • 发表排期:
      查重要求:
    • 有无课题:
      有无回复:
    • 我的学历:
      我的职称:
    • 审稿费用:
      版面费用:
    • 稿       费:
      稿件字数:
    • 投稿难度:
    • 该刊可发:
    • 投稿主题:
匿名: 验证码: 点击切换验证码
    • 1、投稿方式:在线投稿。

      2、刊内网址(202506期):

      https://www.sciencedirect.com/journal/journal-of-pharmaceutical-analysis

      https://www.editorialmanager.com/jpa/(投稿系统)

      3、西安交通大学期刊中心官网:

      http://qkzx.xjtu.edu.cn/index.htm

      4、刊内邮箱:jpasubmit@126.com;jpa2011@xjtu.edu.cn

       官网邮箱:jpaeditor@xjtu.edu.cn

      5、刊内电话:029-88960092

       官网电话:029-82657423

      6、出刊日期:月刊,一年出版12期。

      7、刊内微信公众号:JPharmAnal

      2026年1月29日星期四

      Guide for authors

      【官网信息】

      Before you begin

      Types of paper

      Contributions

      falling into the following categories will be considered for

      publication: Original research article, Review paper, Perspective, Short

      communication, Editorial, Comment, News, and Research highlight. The

      detailed requirement for each article type is available HERE.

      Please

      ensure that you select the appropriate article type from the list of

      options when making your submission. Authors contributing to special

      issues should ensure that they select the special issue article type

      from this list, e.g., SI: Single-cell and ST Omics-Review paper.

      Submission checklist

      You

      can use this list to carry out a final check of your submission before

      you send it to the journal for review. Please check the relevant section

      in this Guide for Authors for more details.

      Ensure that the following items are present:

      One author has been designated as the corresponding author with contact details:

      E-mail address

      Full postal address

      All necessary files have been uploaded:

      Manuscript

      Include keywords

      All figures (include relevant captions)

      All tables (including titles, description, footnotes)

      Ensure all figure and table citations in the text match the files provided

      Indicate clearly if color should be used for any figures in print

      Graphical Abstracts / Highlights files (where applicable)

      Supplemental files (where applicable)

      Further considerations:

      Manuscript has been 'spell checked' and 'grammar checked'

      All references mentioned in the Reference List are cited in the text, and vice versa

      Permission has been obtained for use of copyrighted material from other sources (including the Internet)

      A competing interests statement is provided, even if the authors have no competing interests to declare

      Journal policies detailed in this guide have been reviewed

      For further information, visit our Support Center.

      Ethics in publishing

      Please see our information on Ethics in publishing.

      Declaration of interest

      All

      authors must disclose any financial and personal relationships with

      other people or organizations that could inappropriately influence

      (bias) their work. Examples of potential competing interests include

      employment, consultancies, stock ownership, honoraria, paid expert

      testimony, patent applications/registrations, and grants or other

      funding. Authors must disclose any interests in two places: 1. A summary

      declaration of interest statement in the title page file (if double

      anonymized) or the manuscript file (if single anonymized). If there are

      no interests to declare then please state this: 'Declarations of

      interest: none'. 2. Detailed disclosures as part of a separate

      Declaration of Interest form, which forms part of the journal's official

      records. It is important for potential interests to be declared in both

      places and that the information matches. More information.

      Declaration of generative AI in scientific writing

      Authors must declare the use of generative AI in the manuscript preparation process upon submission of the paper.

      Elsevier

      recognizes the potential of generative AI and AI-assisted technologies

      (“AI Tools”), when used responsibly, to help researchers work

      efficiently, gain critical insights fast and achieve better outcomes.

      Increasingly, these tools, including AI agents and deep research tools,

      are helping researchers to synthesize complex literature, provide an

      overview of a field or research question, identify research gaps,

      generate ideas, and provide tailored support for tasks such as content

      organization and improving language and readability.

      Authors

      preparing a manuscript for an Elsevier journal can use AI Tools to

      support them. However, these tools must never be used as a substitute

      for human critical thinking, expertise and evaluation. AI technology

      should always be applied with human oversight and control.

      Ultimately, authors are responsible and accountable for the contents of their work. This includes accountability for:

      Carefully

      reviewing and verifying the accuracy, comprehensiveness, and

      impartiality of all AI-generated output (including checking the sources,

      as AI-generated references can be incorrect or fabricated).

      Editing

      and adapting all material thoroughly to ensure the manuscript

      represents the author’s authentic and original contribution and reflects

      their own analysis, interpretation, insights and ideas.

      Ensuring

      the use of any tools or sources, AI-based or otherwise, is made clear

      and transparent to readers. If AI Tools have been used, we require a

      disclosure statement upon submission; please see example below.

      Ensuring

      the manuscript is developed in a way that safeguards data privacy,

      intellectual property and other rights, by checking the terms and

      conditions of any AI tool that is used.

      Finally,

      authors must not list or cite AI Tools as an author or co-author on the

      manuscript since authorship implies responsibilities and tasks that can

      only be attributed to, and performed by, humans.

      The

      use of AI Tools in the manuscript preparation process must be declared

      by adding a statement at the end of the manuscript when the paper is

      first submitted. The statement will appear in the published work and

      should be placed in a new section before the references list.

      An example:

      Title of new section: Declaration of generative AI and AI-assisted technologies in the manuscript preparation process.

      Statement:

      During the preparation of this work the author(s) used [NAME OF TOOL /

      SERVICE] in order to [REASON]. After using this tool/service, the

      author(s) reviewed and edited the content as needed and take(s) full

      responsibility for the content of the published article.

      The

      declaration does not apply to the use of basic tools, such as tools

      used to check grammar, spelling and references. If you have nothing to

      disclose, you do not need to add a statement.

      Please

      read Elsevier’s author policy on the use of generative AI and

      AI-assisted technologies, which can be found in our generative AI

      policies for journals.

      Please

      note: to protect authors’ rights and the confidentiality of their

      research, this journal does not currently allow the use of generative AI

      or AI-assisted technologies such as ChatGPT or similar services by

      reviewers or editors in the peer review and manuscript evaluation

      process, as is stated in our generative AI policies for journals. We are

      actively evaluating compliant AI Tools and may revise this policy in

      the future.

      Submission declaration and verification

      Submission

      of an article implies that the work described has not been published

      previously (except in the form of an abstract, a published lecture or

      academic thesis, see 'Multiple, redundant or concurrent publication' for

      more information), that it is not under consideration for publication

      elsewhere, that its publication is approved by all authors and tacitly

      or explicitly by the responsible authorities where the work was carried

      out, and that, if accepted, it will not be published elsewhere in the

      same form, in English or in any other language, including electronically

      without the written consent of the copyright-holder. To verify

      compliance, your article may be checked by Crossref Similarity Check and

      other originality or duplicate checking software.

      Preprints

      Please

      note that preprints can be shared anywhere at any time, in line with

      Elsevier's sharing policy. Sharing your preprints e.g. on a preprint

      server will not count as prior publication (see 'Multiple, redundant or

      concurrent publication' for more information).

      Use of inclusive language

      Inclusive

      language acknowledges diversity, conveys respect to all people, is

      sensitive to differences, and promotes equal opportunities. Content

      should make no assumptions about the beliefs or commitments of any

      reader; contain nothing which might imply that one individual is

      superior to another on the grounds of age, gender, race, ethnicity,

      culture, sexual orientation, disability or health condition; and use

      inclusive language throughout. Authors should ensure that writing is

      free from bias, stereotypes, slang, reference to dominant culture and/or

      cultural assumptions. We advise to seek gender neutrality by using

      plural nouns ("clinicians, patients/clients") as default/wherever

      possible to avoid using "he, she," or "he/she." We recommend avoiding

      the use of descriptors that refer to personal attributes such as age,

      gender, race, ethnicity, culture, sexual orientation, disability or

      health condition unless they are relevant and valid. When coding

      terminology is used, we recommend to avoid offensive or exclusionary

      terms such as "master", "slave", "blacklist" and "whitelist". We suggest

      using alternatives that are more appropriate and (self-) explanatory

      such as "primary", "secondary", "blocklist" and "allowlist". These

      guidelines are meant as a point of reference to help identify

      appropriate language but are by no means exhaustive or definitive.

      Reporting sex- and gender-based analyses

      Reporting guidance

      For

      research involving or pertaining to humans, animals or eukaryotic

      cells, investigators should integrate sex and gender-based analyses

      (SGBA) into their research design according to funder/sponsor

      requirements and best practices within a field. Authors should address

      the sex and/or gender dimensions of their research in their article. In

      cases where they cannot, they should discuss this as a limitation to

      their research's generalizability. Importantly, authors should

      explicitly state what definitions of sex and/or gender they are applying

      to enhance the precision, rigor and reproducibility of their research

      and to avoid ambiguity or conflation of terms and the constructs to

      which they refer (see Definitions section below). Authors can refer to

      the Sex and Gender Equity in Research (SAGER) guidelines and the SAGER

      guidelines checklist. These offer systematic approaches to the use and

      editorial review of sex and gender information in study design, data

      analysis, outcome reporting and research interpretation - however,

      please note there is no single, universally agreed-upon set of

      guidelines for defining sex and gender.

      Definitions

      Sex

      generally refers to a set of biological attributes that are associated

      with physical and physiological features (e.g., chromosomal genotype,

      hormonal levels, internal and external anatomy). A binary sex

      categorization (male/female) is usually designated at birth ("sex

      assigned at birth"), most often based solely on the visible external

      anatomy of a newborn. Gender generally refers to socially constructed

      roles, behaviors, and identities of women, men and gender-diverse people

      that occur in a historical and cultural context and may vary across

      societies and over time. Gender influences how people view themselves

      and each other, how they behave and interact and how power is

      distributed in society. Sex and gender are often incorrectly portrayed

      as binary (female/male or woman/man) and unchanging whereas these

      constructs actually exist along a spectrum and include additional sex

      categorizations and gender identities such as people who are

      intersex/have differences of sex development (DSD) or identify as

      non-binary. Moreover, the terms "sex" and "gender" can be

      ambiguous--thus it is important for authors to define the manner in

      which they are used. In addition to this definition guidance and the

      SAGER guidelines, the resources on this page offer further insight

      around sex and gender in research studies.

      Author contributions

      For

      transparency, we require corresponding authors to provide co-author

      contributions to the manuscript using the relevant CRediT roles. The

      CRediT taxonomy includes 14 different roles describing each

      contributor's specific contribution to the scholarly output. The roles

      are: Conceptualization; Data curation; Formal analysis; Funding

      acquisition; Investigation; Methodology; Project administration;

      Resources; Software; Supervision; Validation; Visualization;

      Roles/Writing - original draft; and Writing - review & editing. Note

      that not all roles may apply to every manuscript, and authors may have

      contributed through multiple roles. More details and an example.

      Changes to authorship

      Authors

      are expected to consider carefully the list and order of authors before

      submitting their manuscript and provide the definitive list of authors

      at the time of the original submission. Any addition, deletion or

      rearrangement of author names in the authorship list should be made only

      before the manuscript has been accepted and only if approved by the

      journal Editor. To request such a change, the Editor must receive the

      following from the corresponding author: (a) the reason for the change

      in author list and (b) written confirmation (e-mail, letter) from all

      authors that they agree with the addition, removal or rearrangement. In

      the case of addition or removal of authors, this includes confirmation

      from the author being added or removed.

      ......

      更多详见:

      https://www.sciencedirect.com/journal/journal-of-pharmaceutical-analysis/publish/guide-for-authors


    验证码: 点击切换验证码